Moreover, the efficacy of PD-1 or PD-L1 inhibitors is limited by multiple factors including PD-1/PD-L1 expression; density of tumor-infiltrating lymphocytes, tumor mutational burden, gut microbiota, circulating cells, and molecules; and patient previous history (136). This evidence concerns the gene CD274 and neoplasm.